Daily Bulletin

Men's Weekly

.

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

Study to evaluate ATG-101, a proprietary PD-L1/4-1BB bispecific antibody

Study will enroll patients with Metastatic/Advanced Solid Tumors and Mature B-Cell Non-Hodgkin Lymphomas

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

SHANGHAI AND HONG KONG, Dec. 20, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company...

Read more: First Patient Dosed in Australia in ATG-101 First-in-Human Trial

Business News

Car Rental as a Practical and Flexible Solution for Travel or Work

The contemporary, hectic way of life is one of ease and adaptability while commuting and working. Regardless of whether one moves around by road, commuting between towns for conferences, or taking a f...

Daily Bulletin - avatar Daily Bulletin

Car Park Markings Melbourne: How Quality Line Marking Shapes Safer Spaces

In modern busy urbanized societies, structured parking areas are necessary in terms of both security and convenience. At a shopping center, business establishment, or a publicly-accessible facility, t...

Daily Bulletin - avatar Daily Bulletin

Cleaning Australia: The Rise of Professional Cleaning Services

The cleaning industry in Australia is booming as more people are opting for professional cleaning services to keep their homes, offices, and businesses spotless. With the increasing demand for cleanli...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business